Brought to you by 
Tanabe, Taisho terminate merger agreement
21 Feb 2002
Executive Summary
Japan's eighth largest drug company Taisho Pharmaceutical will merge with the tenth largest, Tanabe Seiyaku. The companies will operate under a holding company, Taisho Tanabe Pharma Group, to become the country's third largest drug developer. Taisho shareholders will get one share in the new company for each share they hold and Tanabe shareholders will receive 0.55 shares in the new company for each of their shares.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tanabe, Taisho terminate merger agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice